A Study on Weight Loss Cause as per the Side Effect of Liraglutide.

Yu J, Lee J, Lee SH, Cho JH, Kim HS

Cardiovascular therapeutics2 Dec 2022Cited by 4 (Europe PMC)

PMID36540096PMCIDPMC9733986DOI10.1155/2022/5201684PepBankPUB-36540096

Summary

PurposeLiraglutide is known to have much lower weight loss effects in real clinical fields than in randomized clinical trials because of its side effects (SE) and discomfort associated with injections. This study is aimed at determining whether the side effects of liraglutide affect weight reduction and its maintenance in real-world practice.MethodsEndocrinologists conducted a retrospective chart review of data from two tertiary university hospitals. All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included. For an average of 3 and 6 months, weight changes due to the presence or absence of SE and discontinuation (MAIN or STOP) of liraglutide were checked.ResultsOnly 40.8% (64/157) of the patients remained on liraglutide for 6 months; 14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+)), and 40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-)). At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline). However, there were no significant differences in the weight loss between the MAIN (p = 0.062) and STOP (p = 0.204) groups. At 6 months, the weight reduction was -2.0 ± 0.5% (p p p p = 0.01) in STOP_SE(+), compared to baseline. SEs also caused no significant differences in weight loss between the MAIN (p = 0.787) and STOP (p = 0.694) groups.ConclusionsOur study confirmed that the side effects of liraglutide did not affect weight reduction. Moreover, in the real world, the continuous rate of liraglutide use is not high, and the weight gradually increases after 3 months. Therefore, in addition to the side effects of liraglutide, the medical staff should consider various factors that affect drug adherence, consider ways to increase compliance, and continue to ensure management so that patients can maintain their weight.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanObservational studyOther
In patients prescribed liraglutide, 40.8% (64 of 157) remained on treatment for 6 months.
In plain wordsIn patients prescribed liraglutide, 40.8% were still taking it after 6 months.
Peptide
Liraglutide
Outcome
Not applicableRemaining on liraglutide for 6 months
Study
n = 157
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion remaining on liraglutide at 6 months
40.8%
all patients
Source sentences
Summary
Only 40.8% (64/157) of the patients remained on liraglutide for 6 months
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009613
02HumanObservational studySafety outcome
In patients prescribed liraglutide, 14.7% (23 of 157) maintained the drug despite side effects.
In plain wordsIn patients prescribed liraglutide, 14.7% kept taking it despite side effects.
Peptide
Liraglutide
Outcome
Not applicableMaintaining liraglutide despite side effects
Study
n = 157
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion maintaining liraglutide despite side effects
14.7%
MAIN_SE(+)
Source sentences
Summary
14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+))
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009614
03HumanObservational studyOther
In patients prescribed liraglutide, 40.1% (63 of 157) discontinued the drug despite not having side effects.
In plain wordsIn patients prescribed liraglutide, 40.1% stopped taking it although they had no side effects.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuing liraglutide without side effects
Study
n = 157
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion discontinuing liraglutide without side effects
40.1%
STOP_SE(-)
Source sentences
Summary
40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-))
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009615
04HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who continued without side effects, body weight fell by 5.9% at 3 months from baseline.
In plain wordsIn patients who kept using liraglutide without side effects, body weight dropped by about 6% after 3 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 3 months, continued with no side effects (MAIN_SE(-))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight change
−5.9%
MAIN_SE(-), 3 months
Source sentences
Summary
At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009601
05HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who continued despite side effects, body weight fell by 7.9% at 3 months from baseline.
In plain wordsIn patients who kept using liraglutide despite side effects, body weight dropped by about 7.9% after 3 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 3 months, continued despite side effects (MAIN_SE(+))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight change
−7.9%
MAIN_SE(+), 3 months
Source sentences
Summary
At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009602
06HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who stopped without side effects, body weight fell by 4.5% at 3 months from baseline.
In plain wordsIn patients who stopped liraglutide without side effects, body weight dropped by about 4.5% after 3 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 3 months, stopped with no side effects (STOP_SE(-))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight change
−4.5%
STOP_SE(-), 3 months
Source sentences
Summary
At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009603
07HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who stopped with side effects, body weight fell by 3.4% at 3 months from baseline.
In plain wordsIn patients who stopped liraglutide because of side effects, body weight dropped by about 3% after 3 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 3 months, stopped with side effects (STOP_SE(+))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight change
−3.4%
STOP_SE(+), 3 months
Source sentences
Summary
At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009604
08HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who continued without side effects, body weight was 2.0% below baseline at 6 months.
In plain wordsIn patients who kept using liraglutide without side effects, body weight was about 2% lower than at the start after 6 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 6 months, continued with no side effects (MAIN_SE(-))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−2%
MAIN_SE(-), 6 months
Source sentences
Summary
At 6 months, the weight reduction was -2.0 ± 0.5% (p p p p = 0.01) in STOP_SE(+), compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009605
09HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who continued despite side effects, body weight was 2.2% below baseline at 6 months.
In plain wordsIn patients who kept using liraglutide despite side effects, body weight was about 2% lower than at the start after 6 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 6 months, continued despite side effects (MAIN_SE(+))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−2.2%
MAIN_SE(+), 6 months
Source sentences
Summary
At 6 months, the weight reduction was -2.0 ± 0.5% (p p p p = 0.01) in STOP_SE(+), compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009606
10HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who stopped without side effects, body weight was 1.7% below baseline at 6 months.
In plain wordsIn patients who stopped liraglutide without side effects, body weight was about 2% lower than at the start after 6 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 6 months, stopped with no side effects (STOP_SE(-))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−1.7%
STOP_SE(-), 6 months
Source sentences
Summary
At 6 months, the weight reduction was -2.0 ± 0.5% (p p p p = 0.01) in STOP_SE(+), compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009607
11HumanObservational studyEfficacy outcome
In patients prescribed liraglutide who stopped with side effects, body weight was 2.0% below baseline at 6 months.
In plain wordsIn patients who stopped liraglutide because of side effects, body weight was about 2% lower than at the start after 6 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change at 6 months, stopped with side effects (STOP_SE(+))
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−2%
STOP_SE(+), 6 months
Source sentences
Summary
At 6 months, the weight reduction was -2.0 ± 0.5% (p p p p = 0.01) in STOP_SE(+), compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009608
12HumanObservational studyEfficacy outcome
In patients who continued liraglutide, weight loss at 3 months did not differ significantly between those with and without side effects.
In plain wordsAmong patients who kept using liraglutide, weight loss was not significantly different between those with and without side effects.
Peptide
Liraglutide
Outcome
No significant changeWeight loss difference with versus without side effects, continued group, 3 months
Study
n: not reported in source
Comparator
Continued without side effects
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
However, there were no significant differences in the weight loss between the MAIN (p = 0.062) and STOP (p = 0.204) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009609
13HumanObservational studyEfficacy outcome
In patients who stopped liraglutide, weight loss at 3 months did not differ significantly between those with and without side effects.
In plain wordsAmong patients who stopped liraglutide, weight loss was not significantly different between those with and without side effects.
Peptide
Liraglutide
Outcome
No significant changeWeight loss difference with versus without side effects, stopped group, 3 months
Study
n: not reported in source
Comparator
Stopped without side effects
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
However, there were no significant differences in the weight loss between the MAIN (p = 0.062) and STOP (p = 0.204) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009610
14HumanObservational studyEfficacy outcome
In patients who continued liraglutide, weight loss at 6 months did not differ significantly between those with and without side effects.
In plain wordsAmong patients who kept using liraglutide, weight loss at 6 months was not significantly different with or without side effects.
Peptide
Liraglutide
Outcome
No significant changeWeight loss difference with versus without side effects, continued group, 6 months
Study
n: not reported in source
Comparator
Continued without side effects
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
SEs also caused no significant differences in weight loss between the MAIN (p = 0.787) and STOP (p = 0.694) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009611
15HumanObservational studyEfficacy outcome
In patients who stopped liraglutide, weight loss at 6 months did not differ significantly between those with and without side effects.
In plain wordsAmong patients who stopped liraglutide, weight loss at 6 months was not significantly different with or without side effects.
Peptide
Liraglutide
Outcome
No significant changeWeight loss difference with versus without side effects, stopped group, 6 months
Study
n: not reported in source
Comparator
Stopped without side effects
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
SEs also caused no significant differences in weight loss between the MAIN (p = 0.787) and STOP (p = 0.694) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals.
Summary · context
All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included.
Show in the study text Report a problemFND-3654009612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.